Dextrose Prolotherapy for Chondromalacia Patella: Can It Help Relieve Knee Pain?
A 2026 randomised controlled trial investigated whether periarticular injections of 5% dextrose could improve pain and knee function in patients with chondromalacia patella. The findings are encouraging, but do they provide sufficient evidence to support prolotherapy as a treatment?
At a glance
Chondromalacia patella refers to changes affecting the articular cartilage on the underside of the kneecap. It may be associated with pain at the front of the knee, particularly during activities such as climbing or descending stairs, squatting, running or sitting with the knee bent for prolonged periods.
However, chondromalacia patella and patellofemoral pain are not interchangeable diagnoses. Not everyone experiencing anterior knee pain has cartilage abnormalities, and not every cartilage abnormality identified on imaging is responsible for symptoms.
A randomised controlled trial published in PM&R in 2026 investigated the effects of periarticular injections of 5% dextrose in 54 patients with chondromalacia patella.
At 24 weeks, participants receiving dextrose demonstrated greater improvements in several measures of pain and knee function than those receiving saline injections.
These findings suggest a potential therapeutic benefit, but they do not establish prolotherapy as a proven treatment for chondromalacia patella. Nor do they demonstrate regeneration of damaged cartilage.
Understanding this distinction is essential when interpreting the emerging evidence.
What is chondromalacia patella, and why can it cause knee pain?
The patella, commonly known as the kneecap, is a small bone situated at the front of the knee. As the knee bends and straightens, the patella moves relative to the femur, forming part of the knee's extensor mechanism.
The posterior surface of the patella is covered by articular cartilage, a specialised tissue that facilitates smooth joint movement and helps distribute mechanical loads.
The term chondromalacia literally means softening of cartilage. In clinical practice, however, it is often used more broadly to describe changes in the cartilage covering the underside of the patella, ranging from relatively mild alterations to more substantial structural damage.
When associated with symptoms, chondromalacia patella may present as pain around or behind the kneecap.
Patients commonly report discomfort when descending stairs, performing squats, running or standing up after sitting for an extended period.
Nevertheless, an important distinction must be made.
Chondromalacia patella describes a structural cartilage abnormality, whereas patellofemoral pain describes a clinical pain condition.
The two may coexist, but they are not synonymous.
A patient may experience patellofemoral pain without significant cartilage damage. Conversely, magnetic resonance imaging (MRI) may identify cartilage changes that do not necessarily explain the patient's symptoms.
This distinction is particularly relevant when assessing research into prolotherapy. Findings obtained in patients diagnosed with chondromalacia patella cannot automatically be applied to everyone experiencing pain at the front of the knee.
Why is prolotherapy being investigated for chondromalacia patella?
Prolotherapy is an injection-based intervention that commonly involves the administration of solutions containing dextrose, a form of glucose.
It has been investigated in several musculoskeletal conditions, including certain tendinopathies, ligament-related disorders and painful joint conditions.
Traditional prolotherapy is based on the hypothesis that injecting specific solutions into selected tissues may stimulate local biological responses associated with tissue adaptation or repair.
However, the mechanisms underlying its potential clinical effects remain incompletely understood.
Biological plausibility should not be confused with demonstrated therapeutic efficacy.
In chondromalacia patella, researchers are primarily interested in whether prolotherapy may help reduce pain, improve knee function and enhance patients' ability to perform everyday activities.
These are clinically meaningful outcomes.
They are not, however, equivalent to demonstrating the regeneration of damaged articular cartilage.
For a broader introduction to the procedure, see our guide to prolotherapy, its proposed mechanisms and the current evidence.
We have also examined the potential applications and limitations of prolotherapy for knee pain.
The 2026 clinical trial: 5% dextrose prolotherapy versus saline injections
One of the most relevant recent developments is a randomised controlled trial published in the journal PM&R:
The study, conducted by Bayır, Köroğlu and Demir, was designed to evaluate the effectiveness of periarticular 5% dextrose prolotherapy in patients with chondromalacia patella.
The investigators recruited 54 participants who had experienced knee pain for at least three months.
Participants were randomly allocated to two treatment groups.
One group received periarticular injections containing 5% dextrose, while the comparison group received saline injections.
Treatment sessions were performed at baseline and subsequently at weeks three and six.
The investigators assessed participants over a 24-week follow-up period, examining pain, patellofemoral symptoms, knee function and health-related quality of life.
Two participants withdrew, leaving 52 patients in the final analysis.
The randomised, double-blind design is an important methodological strength.
Random allocation helps reduce differences between treatment groups, while blinding can limit the influence of patients' and investigators' expectations on the reported outcomes.
Nevertheless, these safeguards do not eliminate the limitations associated with a relatively small, single-centre trial.
What did the researchers find?
Both treatment groups experienced improvements compared with their baseline assessments.
This is an important finding in itself.
Improvements following an injection procedure cannot automatically be attributed to the pharmacological or biological properties of the injected substance.
Other factors, including the clinical course of the condition, contextual effects of treatment and responses associated with the injection procedure, may contribute to changes in symptoms.
However, at the 24-week assessment, the participants receiving 5% dextrose demonstrated better outcomes than those receiving saline across several measures.
The reported differences favoured dextrose in relation to pain intensity, patellofemoral symptoms, knee function and the number of tender points.
A measure of physical health-related quality of life also favoured the dextrose group.
The between-group difference in pain, assessed using a visual analogue scale, was approximately 1.67 points in favour of dextrose.
The Kujala score, a questionnaire commonly used to assess symptoms and functional limitations associated with patellofemoral disorders, was approximately 9.3 points higher in the prolotherapy group.
These results suggest that, within the population studied and using the specified injection protocol, 5% dextrose prolotherapy produced greater clinical improvements than saline injections.
The findings are encouraging.
However, the clinical relevance and generalisability of these differences require careful consideration.
What does the study demonstrate — and what remains uncertain?
The 2026 trial provides more informative evidence than an uncontrolled clinical observation because it includes random allocation and a comparison group.
It therefore represents a useful contribution to the literature on prolotherapy for chondromalacia patella.
Nevertheless, several limitations should be considered before translating the findings into routine clinical practice.
A relatively small study population
The trial enrolled 54 participants, with 52 included in the final analysis.
Although this sample can identify potentially meaningful treatment effects, larger studies are needed to establish the reliability of the findings and determine whether similar results occur in different patient populations.
A relatively small trial also has limited capacity to identify uncommon adverse events.
A follow-up period of 24 weeks
The investigators assessed outcomes over approximately six months.
This provides useful information about short- to medium-term clinical responses, but it does not establish whether improvements persist over one or several years.
Longer-term studies are needed to evaluate the durability of treatment effects.
One specific treatment protocol
The study investigated periarticular injections of 5% dextrose administered on three occasions.
It did not establish whether different concentrations, injection sites, treatment intervals or numbers of sessions would produce comparable results.
Consequently, its findings should not be generalised to every procedure described as dextrose prolotherapy.
Clinical improvement is not evidence of cartilage regeneration
Perhaps the most important limitation concerns the outcomes measured.
The study focused primarily on pain, symptoms, physical function and quality of life.
It did not demonstrate that dextrose injections restored or regenerated damaged patellar cartilage.
An improvement in symptoms is clinically valuable, but it must not be presented as proof of structural tissue repair.
Can prolotherapy regenerate knee cartilage?
Cartilage regeneration is frequently discussed in connection with treatments described as regenerative medicine.
However, the term requires careful interpretation.
A treatment may reduce pain and improve physical function without producing a measurable structural change in articular cartilage.
For example, a patient may become more comfortable walking, climbing stairs or exercising after treatment.
These improvements are important from a clinical perspective.
They do not necessarily indicate that cartilage thickness, composition or structural integrity has been restored.
Demonstrating cartilage regeneration would require appropriately designed studies using validated structural assessments, potentially including advanced imaging techniques and longitudinal comparisons.
The 2026 trial did not provide such evidence.
Its findings support a more limited conclusion:
In the patients studied, periarticular 5% dextrose injections were associated with better pain and functional outcomes than saline injections at 24 weeks.
That is a clinically relevant observation, but it is not evidence of cartilage regrowth.
For further discussion of the distinction between biological hypotheses and demonstrated clinical outcomes, our scientific references and evidence resources provide additional background.
Why did the researchers use 5% dextrose?
Dextrose concentration is an important consideration when interpreting studies of prolotherapy.
Different injection protocols use different concentrations, depending on the condition being investigated, the intended anatomical target and the proposed therapeutic mechanism.
Traditional prolotherapy frequently involves hypertonic dextrose solutions, while lower concentrations, including 5% dextrose, are also used in certain perineural injection approaches.
These techniques should not automatically be regarded as interchangeable.
In the chondromalacia patella trial, the investigators used periarticular injections of 5% dextrose.
They did not directly compare this concentration with 15%, 20% or 25% dextrose.
Therefore, the findings cannot establish that 5% dextrose is the optimal concentration for chondromalacia patella or other knee conditions.
Nor do they establish that a higher concentration would necessarily be more effective.
Differences in concentration, anatomical target and injection technique may influence treatment effects, and each protocol requires appropriate clinical investigation.
This is one reason why studies grouped under the broad heading of prolotherapy should be interpreted individually rather than assumed to evaluate an identical intervention.
Further research is discussed in our scientific literature section.
Has prolotherapy previously been studied in chondromalacia patella?
The 2026 randomised trial is not the first investigation of prolotherapy in this condition.
In 2014, Hauser and Sprague published a retrospective study reporting improvements in pain and function among patients with chondromalacia patella who underwent prolotherapy.
The study is available through PubMed.
Although the reported improvements were of interest, the retrospective design imposed substantial methodological limitations.
Without randomisation and an appropriate control group, it is difficult to determine how much of the observed improvement can be attributed specifically to the treatment.
Changes may also reflect the natural course of symptoms, other interventions or additional factors that were not adequately controlled.
The 2026 trial therefore represents an important methodological advance because it incorporates a randomised comparison with saline injections.
Nevertheless, one relatively small randomised trial does not resolve all uncertainties.
Further independent studies, ideally conducted across multiple centres and involving larger populations, are required.
What about prolotherapy for patellofemoral pain syndrome?
Chondromalacia patella and patellofemoral pain syndrome are closely related topics in the clinical literature, but they should not be treated as identical conditions.
Patellofemoral pain is generally characterised by pain around or behind the patella during activities that load the patellofemoral joint while the knee is flexed.
Such activities commonly include squatting, running, stair negotiation and prolonged sitting.
The condition is diagnosed primarily through clinical assessment rather than the identification of a particular cartilage abnormality.
This distinction matters because research involving patients with patellofemoral pain cannot necessarily be used to draw conclusions about structurally confirmed chondromalacia.
A 2026 case report also described ultrasound-guided dextrose prolotherapy combined with an exercise programme in a young adult with patellofemoral pain syndrome.
Clinical and functional improvements were reported.
However, a single case report cannot establish treatment efficacy.
Furthermore, because the patient received both injections and exercise-based treatment, it is not possible to determine the independent contribution of the injection procedure.
Such reports may generate hypotheses for future research, but they should not be interpreted as evidence supporting routine clinical use.
Prolotherapy or physiotherapy: are they alternatives?
Exercise-based rehabilitation remains central to the management of patellofemoral pain.
A 2024 best-practice guide published in the British Journal of Sports Medicine synthesised evidence from systematic reviews, patient perspectives and expert clinical reasoning.
The recommendations emphasised education and exercise therapy as the foundation of treatment, with additional interventions considered according to individual clinical circumstances.
Exercise programmes may address lower-limb strength, movement control, functional capacity and the progressive management of activities that provoke symptoms.
The aim is not simply to reduce pain temporarily.
It is also to improve the patient's ability to tolerate the mechanical demands of everyday life, work and sport.
An injection procedure, even when associated with symptom relief, does not automatically restore muscular strength, movement capacity or tolerance of physical loading.
For this reason, prolotherapy should not be presented as a general replacement for physiotherapy.
The more relevant clinical question is whether a particular intervention offers additional benefit within a comprehensive, individually tailored management programme.
At present, the evidence is insufficient to define a routine role for prolotherapy alongside rehabilitation in chondromalacia patella.
The relationship between injection-based interventions and functional recovery is also discussed in our article on prolotherapy and sports injuries.
Prolotherapy, PRP, corticosteroids or hyaluronic acid: which injection is best?
Patients with persistent knee pain may encounter several injection-based treatment options.
These include corticosteroids, hyaluronic acid, platelet-rich plasma (PRP) and dextrose-based prolotherapy.
However, the available evidence does not support a universal ranking of these interventions across all knee disorders.
Each treatment has a different proposed mechanism of action, and the quality and relevance of the supporting evidence vary according to the condition being treated.
In particular, results obtained in knee osteoarthritis should not automatically be extrapolated to chondromalacia patella.
Although both conditions may involve cartilage abnormalities, they differ in their clinical characteristics, affected populations and potentially relevant treatment targets.
The 2026 prolotherapy trial compared 5% dextrose with saline.
It did not compare dextrose with PRP, corticosteroids or hyaluronic acid.
Consequently, it cannot establish whether prolotherapy is superior or inferior to these alternatives.
The most appropriate treatment depends on an accurate diagnosis, the patient's clinical presentation, previous management and the strength of the evidence supporting each option.
When might prolotherapy be considered for chondromalacia patella?
The findings of the 2026 trial suggest that periarticular 5% dextrose prolotherapy warrants further investigation as a potential treatment for selected patients with chondromalacia patella.
However, this does not amount to a recommendation for routine use.
The presence of cartilage changes on MRI is not, in itself, an indication for prolotherapy.
Before considering an injection-based intervention, clinicians need to establish whether the imaging findings are consistent with the patient's symptoms and whether other factors may be contributing to the pain.
It is also important to consider the patient's functional limitations, previous treatments, response to rehabilitation and individual goals.
Potential benefits should be discussed alongside uncertainties, procedural risks and available alternatives.
Patients should not be led to expect cartilage regeneration, as this outcome has not been demonstrated by the available trial.
At present, prolotherapy is best regarded as an intervention with emerging but limited evidence in this specific condition.
What are the potential risks of dextrose injections?
Dextrose is a naturally occurring sugar, but its presence in the body does not mean that an injection procedure is risk-free.
Possible adverse effects include temporary discomfort at the injection site, local tenderness, bruising or swelling.
As with other procedures involving needles, there are also potential risks of bleeding, infection and accidental injury to nearby anatomical structures.
The overall safety profile depends on several factors, including the injection site, technique, solution used, the patient's medical history and the practitioner's expertise.
Small clinical trials are not sufficiently powered to exclude uncommon complications.
Further research is therefore needed to assess both the effectiveness and long-term safety of dextrose prolotherapy in patients with chondromalacia patella.
What does the 2026 trial change?
The publication of this trial adds a valuable piece of evidence to a field in which many proposed applications have historically been supported by relatively limited or heterogeneous research.
Earlier studies had already explored prolotherapy in chondromalacia patella, but the 2026 trial provides a more rigorous comparison through its randomised, double-blind design.
Its findings suggest that periarticular injections of 5% dextrose may improve certain clinical outcomes more effectively than saline injections over a 24-week period.
That is a meaningful development.
However, the small sample size, single-centre design and limited follow-up mean that the findings require confirmation.
The study also does not establish the optimal injection protocol or demonstrate structural cartilage repair.
The evidence has advanced, but important clinical questions remain unanswered.
Conclusion: promising clinical findings, but not proof of cartilage regeneration
Chondromalacia patella is a complex clinical condition in which structural cartilage changes and anterior knee pain do not always correspond directly.
The 2026 randomised controlled trial published in PM&R suggests that periarticular injections of 5% dextrose may offer greater improvements in pain and knee function than saline injections in selected patients with chondromalacia patella.
These findings deserve attention because they arise from a controlled clinical investigation rather than anecdotal reports.
Nevertheless, a favourable result in a relatively small study does not establish universal treatment efficacy.
Nor does improvement in pain or function demonstrate that damaged cartilage has regenerated.
Future research will need to determine whether these benefits can be reproduced in larger populations, how long they persist, which patients may be most likely to respond and whether prolotherapy offers meaningful additional benefit alongside established conservative management.
For patients and clinicians alike, the distinction is essential.
Promising evidence should be recognised — but it should not be presented as scientific certainty.
Frequently Asked Questions
Does dextrose prolotherapy work for chondromalacia patella?
A 2026 randomised controlled trial reported greater improvements in several measures of pain and knee function following periarticular 5% dextrose injections compared with saline. However, larger studies are required before its effectiveness can be established with greater certainty.
Can prolotherapy regenerate damaged kneecap cartilage?
There is currently insufficient evidence to conclude that prolotherapy regenerates damaged patellar cartilage. The 2026 trial assessed clinical outcomes, including pain and function, but did not demonstrate structural cartilage regeneration.
What is injected during dextrose prolotherapy?
Dextrose prolotherapy involves injections containing dextrose, a form of glucose. The 2026 chondromalacia patella trial investigated periarticular injections of a 5% dextrose solution.
Is 5% dextrose better than 15% or 25% dextrose?
The chondromalacia patella trial did not compare different dextrose concentrations. It therefore cannot establish whether 5% dextrose is more or less effective than higher concentrations.
Does pain at the front of the knee always mean chondromalacia patella?
No. Anterior knee pain can arise from several conditions. A clinical assessment is needed to determine the likely source of symptoms and whether imaging investigations are appropriate.
Can prolotherapy replace physiotherapy?
Current evidence does not support prolotherapy as a replacement for physiotherapy. Education, exercise therapy and progressive functional rehabilitation remain central components of patellofemoral pain management.
How many injections were given in the 2026 trial?
Participants received three treatment sessions: at baseline, week three and week six. This was the protocol investigated in the trial and should not be interpreted as a universally recommended treatment schedule.
Is dextrose prolotherapy safe?
Temporary injection-site pain, tenderness, bruising and swelling may occur. As with any injection procedure, there are also risks such as infection, bleeding and injury to nearby structures. Larger studies are needed to characterise uncommon adverse events and long-term safety.
Scientific References
Primary study
Bayır YB, Köroğlu Ö, Demir Y. Efficacy of 5% dextrose prolotherapy compared with saline injections for chondromalacia patella: A randomized controlled trial. PM&R. 2026;18(10):1133–1144.
Clinical guidelines and supporting literature
Neal BS et al. Best practice guide for patellofemoral pain based on synthesis of a systematic review, the patient voice and expert clinical reasoning. British Journal of Sports Medicine. 2024.
Willy RW et al. Patellofemoral Pain: Clinical Practice Guidelines. Journal of Orthopaedic & Sports Physical Therapy. 2019.
Hauser RA, Sprague IS. Outcomes of prolotherapy in chondromalacia patella patients: improvements in pain level and function.
Furigay KRA et al. Ultrasound-guided dextrose prolotherapy on regeneration of knee structures, pain, and function of a patient with patellofemoral pain syndrome: a case report. 2026.
Editorial note: This article provides an independent, evidence-based overview of the published scientific literature. It is intended for educational purposes and does not replace individual medical assessment or constitute a recommendation for a specific treatment.
Comments